AnaptysBio, Inc. (ANAB) Given Buy Rating at Stifel Nicolaus
Stifel Nicolaus reaffirmed their buy rating on shares of AnaptysBio, Inc. (NASDAQ:ANAB) in a research note released on Friday. Stifel Nicolaus currently has a $76.00 target price on the biotechnology company’s stock, up from their previous target price of $35.00.
ANAB has been the subject of several other reports. Credit Suisse Group upped their target price on AnaptysBio from $34.00 to $38.00 and gave the company an outperform rating in a report on Friday, August 25th. Royal Bank Of Canada upped their target price on AnaptysBio from $40.00 to $79.00 and gave the company an outperform rating in a report on Tuesday, October 10th. Zacks Investment Research raised AnaptysBio from a hold rating to a buy rating and set a $28.00 target price for the company in a report on Wednesday, August 30th. JMP Securities upped their target price on AnaptysBio from $45.00 to $82.00 and gave the company an outperform rating in a report on Tuesday, October 10th. Finally, Robert W. Baird initiated coverage on AnaptysBio in a report on Monday, July 10th. They set an outperform rating and a $36.00 target price for the company. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of Buy and an average target price of $71.71.
AnaptysBio (ANAB) opened at 66.72 on Friday. The company’s 50-day moving average price is $36.95 and its 200-day moving average price is $27.78. The stock’s market cap is $1.36 billion. AnaptysBio has a 1-year low of $15.17 and a 1-year high of $74.00.
AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.29. The company had revenue of $7.00 million for the quarter, compared to the consensus estimate of $3.45 million. Analysts predict that AnaptysBio will post ($1.99) EPS for the current year.
In related news, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $24.35, for a total value of $901,924.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Holdings A/S Novo sold 70,706 shares of the stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $23.31, for a total value of $1,648,156.86. Following the completion of the transaction, the insider now directly owns 3,009,949 shares of the company’s stock, valued at $70,161,911.19. The disclosure for this sale can be found here. Insiders sold a total of 1,133,940 shares of company stock valued at $24,223,316 over the last three months.
A number of hedge funds have recently modified their holdings of the stock. Artal Group S.A. lifted its position in AnaptysBio by 459.4% in the second quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock worth $5,983,000 after purchasing an additional 205,310 shares during the period. JPMorgan Chase & Co. acquired a new stake in AnaptysBio in the first quarter worth approximately $3,851,000. Geode Capital Management LLC acquired a new stake in AnaptysBio in the first quarter worth approximately $1,522,000. Iguana Healthcare Management LLC acquired a new stake in AnaptysBio in the first quarter worth approximately $1,388,000. Finally, Boxer Capital LLC acquired a new stake in AnaptysBio in the first quarter worth approximately $1,388,000. 71.35% of the stock is owned by institutional investors and hedge funds.
AnaptysBio Company Profile
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.